Cognizant and Veeva’s Study on Nutrition and Bone Health: Key Insights for Investors
Cognizant Technology Solutions (CTSH), Veeva Systems Inc (VEEV) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
In a recent update from Cognizant Technology Solutions and Veeva Systems, a clinical study titled ‘Nutrition, Microbiome and Bone Health During Early Life Related to Health’ has been completed. Sponsored by Société des Produits Nestlé, the study aimed to explore the relationship between nutrition, microbiome, and bone health in infants from birth to three years. This research is significant as it seeks to understand how early-life nutrition impacts long-term health outcomes.
The study did not involve any specific interventions but focused on observing two groups of healthy infants and their mothers over different time frames. The primary goal was to collect and analyze fecal, urine, and breastmilk samples to track microbiome and bone health trajectories.
Designed as an observational cohort study, it employed a prospective time perspective. The study followed 690 infants and their mothers in two groups, one from birth to 12 months and the other from 6 months to 3 years, without any interventions.
Key dates include the study’s start on October 13, 2021, and its completion with the last update submitted on November 26, 2025. These timelines are crucial for investors as they indicate the study’s progress and data availability.
The completion of this study could positively impact Cognizant Technology Solutions and Veeva Systems’ stock performance by enhancing their reputation in the healthcare technology sector. With increasing interest in health tech solutions, this study positions these companies favorably against competitors.
The study is now completed, with further details accessible on the ClinicalTrials portal.
